Sage stock plummeted Monday after the Food and Drug Administration approved its drug, Zurzuvae, to treat postpartum depression, but not as a medication for major depressive disorder.
Zurzuvae is the first oral treatment for postpartum depression, a condition that affects about 10%-15% of people following pregnancy. Previously, the only option for patients was Sage…